Citations

Showing 10 of 108015 citations.

Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines
Huemer, Martina , Kožich, Viktor , Rinaldo, Piero, Baumgartner, Matthias R. , Merinero, B., Pasquini, Elisabetta , Ribes, Antònia , Blom, Henk J. , Ribes, Antonia , Baumgartner, Matthias

Mayo Clinic

Journal of Inherited Metabolic Disease | March 11, 2015 | Volume: 38 | Issue: 6 | Pages: 1007-1019

10.1007/s10545-015-9830-z | PMID 25762406 Get It

AbstractNewborn screening (NBS) is justified if early intervention is effective in a disorder generally not detected early in life on a clinical basis, and if sensitive and specific biochemical markers exist. Experience with NBS for homocystinurias and methylation disorders is limited. However, there is robust evidence for the success of early treatment with diet, betaine and/or pyridoxine for CBS deficiency and good evidence for the success of early betaine treatment in severe MTHFR deficiency. These conditions can be screened in dried blood spots by determining methionine (Met), methionine‐to‐phenylanine (Met/Phe) ratio, and total homocysteine (tHcy) as a second tier marker. Therefore, we recommend NBS for cystathionine beta‐synthase and severe MTHFR deficiency. Weaker evidence is available for the disorders of intracellular cobalamin metabolism. Early treatment is clearly of advantage for patients with the late‐onset cblC defect. In the early‐onset type, survival and non‐neurological symptoms improve but the effect on neurocognitive development is uncertain. The cblC defect can be screened by measuring propionylcarnitine, propionylcarnitine‐to‐acetylcarnitine ratio combined with the second tier markers methylmalonic acid and tHcy. For the cblE and cblG defects, evidence for the benefit of early treatment is weaker; and data on performance of Met, Met/Phe and tHcy even more limited. Individuals homozygous or compound heterozygous for MAT1A mutations may benefit from detection by NBS using Met, which on the other hand also detects asymptomatic heterozygotes. Clinical and laboratory data is insufficient to develop any recommendation on NBS for the cblD, cblF, cblJ defects, glycineN‐methyltransferase‐, S‐adenosylhomocysteinehydrolase‐ and adenosine kinase deficiency.
Measurement of psychosine in dried blood spots — a possible improvement to newborn screening programs for Krabbe disease
Turgeon, Coleman , Orsini, Joseph J. , Sanders, Karen A., Magera, Mark J , Langan, Thomas J. , Escolar, Maria L. , Duffner, Patricia K., Oglesbee, Devin , Gavrilov, Dimitar , Tortorelli, Silvia , Rinaldo, Piero, Raymond, Kimiyo , Matern, Dietrich , Turgeon, Coleman T, Oglesbee, Devin

Mayo Clinic

Journal of Inherited Metabolic Disease | March 11, 2015 | Volume: 38 | Issue: 5 | Pages: 923-929

10.1007/s10545-015-9822-z | PMID 25762404 Get It

AbstractBackgroundNewborn screening (NBS) for Krabbe disease (KD) in New York and Missouri is conducted by measuring galactocerebrosidase (GALC) activity using tandem mass spectrometry (MS/MS). These NBS efforts have shown that the incidence of KD is unexpectedly low (1:400,000) while many individuals (ca. 1:6000) with reduced GALC activity and genotypes of uncertain significance are detected and subjected to follow up testing. Psychosine (PSY) is a putative marker of KD progression and can be measured in dried blood spots (DBS). We sought to determine the role that PSY levels play in NBS for KD, follow up, and treatment monitoring.MethodsPSY was eluted from DBS with methanol containing N,N‐dimethyl‐D‐erythro‐sphingosine as internal standard (IS). Liquid chromatography‐MS/MS was conducted over 17 minutes in the multiple reaction monitoring positive mode to follow the precursor to product species transitions for PSY and IS. Separation of the structural isomers PSY and glucosylsphingosine was accomplished by hydrophilic interaction liquid chromatography.ResultsPre‐analytical and analytical factors were studied and revealed satisfactory results. PSY was also measured in DBS collected from controls (range: <8 nmol/L, N = 220), KD patients at various disease stages (range: 8–112, N = 26), and GALC mutation carriers (range: <15 nmol/L, N = 18).ConclusionsPSY measurement in DBS could serve as a 2nd tier assay in NBS for KD, simplify and reduce the cost of follow up protocols, help determine disease progression, and be used to monitor KD patients following hematopoietic stem cell transplantation. However, additional chronological measurements of PSY in KD patients are required to confirm these possibilities.
Dual roles of autologous CD8+ T cells in hematopoietic progenitor cell mobilization and engraftment
Russell, Athena , Malik, Sunita , Litzow, Mark R. , Gastineau, Dennis A., Gastineau, Dennis, Gastineau, Dennis A. , Roy, Vivek , Zubair, Abba C.

Mayo Clinic

Transfusion | March 11, 2015 | Volume: 55 | Issue: 7 | Pages: 1758-1765

10.1111/trf.13073 | PMID 25757596 Get It

BACKGROUNDPoor marrow cellularity alone cannot explain poor hematopoietic progenitor cell (HPC) mobilization. This study assessed the role of CD8+ T cells in HPC cell mobilization and engraftment.STUDY DESIGN AND METHODSMobilization and engraftment were assessed in 192 autologous HPC donors. CD34+, CD4+, and CD8+ T‐cell contents in apheresis products were evaluated. Using a chemotaxis assay, we assessed the effect of purified autologous CD8+ T cells from low and high mobilizers on HPC migration from high to low stromal cell–derived factor (SDF‐1α) concentration gradients. We also assessed CD8+ T‐cell content association with days to neutrophil engraftment.RESULTSThe median number of CD34+ cells/kg was 4.7 × 106. Patients were categorized according to their total CD34+ cell collection quartile distribution into low, moderate, and high mobilizers. We found that HPC products from low mobilizers contained more CD8+ T cells than HPC products from moderate and high mobilizers. Chemotaxis assays showed depletion of CD8+ T cells enhances HPC mobilization independent of SDF‐1α concentration. Neutrophil engraftment analysis showed that the higher the CD8+ T‐cell content per unit CD34+ cell, the faster the rate of engraftment.CONCLUSIONOur findings suggest CD8+ T cells inhibit HPC mobilization and facilitate homing and engraftment.
An unusual case of near‐fatal hemolytic anemia treated with erythrocytapheresis and therapeutic plasma exchange
Dasararaju, Radhika, Adamski, Jill

Mayo Clinic

Transfusion | March 11, 2015 | Volume: 55 | Issue: 3 | Pages: 475-475

10.1111/trf.12857 | PMID 25759128 Get It

Decision-Making for Destination Therapy Left Ventricular Assist Devices
Jones, J. K. N. , Nowels, Carolyn T., Matlock, Daniel D. , McIlvennan, Colleen K, Jones, Jacqueline , Allen, Larry A. , Swetz, Keith M. , Nowels, Carolyn, McIlvennan, Colleen Kelley , Lindenfeld, JoAnn , Matlock, Daniel D

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 11, 2015 | Volume: 8 | Issue: 2 | Pages: 172-178

10.1161/circoutcomes.114.001276 | PMID 25759442 Get It

Background— Implanting centers often require the identification of a dedicated caregiver before destination therapy left ventricular assist device (DT LVAD) implantation; however, the caregiver experience surrounding this difficult decision is relatively unexplored. Methods and Results— From October 2012 through July 2013, we conducted semistructured, in-depth interviews with caregivers of patients considering DT LVAD. Data were analyzed using a mixed inductive and deductive approach. We interviewed 17 caregivers: 10 caregivers of patients living with DT LVAD, 6 caregivers of patients who had died with DT LVAD, and 1 caregiver of a patient who had declined DT LVAD. The themes identified, which could also be considered dialectical tensions, are broadly interpreted under 3 domains mapping to decision context, process, and outcome: (1) the stark decision context, with tension between hope and reality; (2) the challenging decision process, with tension between wanting loved ones to live and wanting to respect loved ones’ wishes; and (3) the downstream decision outcome, with tension between gratitude and burden. Conclusions— Decision-making surrounding DT LVAD should incorporate decision support for patients and caregivers. This should include a focus on caregiver burden and the predictable tensions that caregivers experience.
Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum
Lahoria, Rajat , Dyck, P. James B. , Macon, William R. , Spinner, Robert J. , Amrami, Kimberly K. , Zeldenrust, Steven R., Tracy, Jennifer A., Crum, Brian A.

Mayo Clinic

Muscle & Nerve | March 11, 2015 | Volume: 52 | Issue: 3 | Pages: 449-454

10.1002/mus.24646 | PMID 25758704 Get It

ABSTRACTIntroductionNeurolymphomatosis (NL) is a rare disorder characterized by invasion of cranial or peripheral nerves, nerve roots, or plexi, usually by aggressive subtypes of non‐Hodgkin lymphoma (NHL). The most common clinical presentation is that of a painful polyneuropathy or polyradiculopathy, followed by cranial neuropathy and, less frequently, by painless polyneuropathy.MethodsClinical and pathologic findings are reported for 2 NL cases.ResultsThe following 2 patients with NL, with disparate clinical presentations, are presented: a patient with subacute onset, painful, multifocal, mixed axonal and demyelinating radiculoplexus neuropathy due to a large B‐cell NHL, who required 2 targeted fascicular nerve biopsies to demonstrate NL; and a patient with a slowly progressive, length‐dependent axonal polyneuropathy due to a low‐grade B‐cell lymphoproliferative disorder, as shown on a diagnostic sural nerve biopsy.ConclusionsThe cases described illustrate the wide clinical spectrum of NL. Muscle Nerve 52:449–454, 2015
Continuous Age- and Sex-Adjusted Reference Intervals of Urinary Markers for Cerebral Creatine Deficiency Syndromes: A Novel Approach to the Definition of Reference Intervals
Mørkrid, Lars , Rowe, Alexander D. , Elgstøen, Katja Benedikte Prestø , Olesen, Jess Have, Ruijter, George J. G. , Tortorelli, Silvia , Kyriakopoulou, Lianna , Wamelink, Mirjam M. C. , Kamp, Jiddeke M. van de , Salomons, Gajja S. , Rinaldo, Piero, Hall, Patricia , Schulze, Andreas

Mayo Clinic

Clinical Chemistry | March 10, 2015 | Volume: 61 | Issue: 5 | Pages: 760-768

10.1373/clinchem.2014.235564 | PMID 25759465 Get It

Abstract BACKGROUND Urinary concentrations of creatine and guanidinoacetic acid divided by creatinine are informative markers for cerebral creatine deficiency syndromes (CDSs). The renal excretion of these substances varies substantially with age and sex, challenging the sensitivity and specificity of postanalytical interpretation. METHODS Results from 155 patients with CDS and 12 507 reference individuals were contributed by 5 diagnostic laboratories. They were binned into 104 adjacent age intervals and renormalized with Box–Cox transforms (Ξ). Estimates for central tendency (μ) and dispersion (σ) of Ξ were obtained for each bin. Polynomial regression analysis was used to establish the age dependence of both μ[log(age)] and σ[log(age)]. The regression residuals were then calculated as z-scores = {Ξ − μ[log(age)]}/σ[log(age)]. The process was iterated until all z-scores outside Tukey fences ±3.372 were identified and removed. Continuous percentile charts were then calculated and plotted by retransformation. RESULTS Statistically significant and biologically relevant subgroups of z-scores were identified. Significantly higher marker values were seen in females than males, necessitating separate reference intervals in both adolescents and adults. Comparison between our reconstructed reference percentiles and current standard age-matched reference intervals highlights an underlying risk of false-positive and false-negative events at certain ages. CONCLUSIONS Disease markers depending strongly on covariates such as age and sex require large numbers of reference individuals to establish peripheral percentiles with sufficient precision. This is feasible only through collaborative data sharing and the use of appropriate statistical methods. Broad application of this approach can be implemented through freely available Web-based software.
Left Atrial Appendage Closure for Atrial Fibrillation—Reply
Holmes, David R. , Reddy, Vivek Y.

Mayo Clinic

JAMA | March 10, 2015 | Volume: 313 | Issue: 10 | Pages: 1057

10.1001/jama.2015.0685 | PMID 25756446 Get It

Building a Central Repository for Research Ethics Consultation Data: A Proposal for a Standard Data Collection Tool
Cho, Mildred K. , Anderson, Nick, Barnard, David , Boyle, Mary B., Capron, Alexander Morgan , Dorfman, Elizabeth, Havard, Kathryn, Reider, Carson, Sadler, John Z. , Sharp, Richard R. , Wilfond, Benjamin S. , McCormick, Jennifer B, Taylor, Holly A. , McCormick, Jennifer Blair , Anderson, Nick, Schwartz, Peter H. , Danis, Marion , Sharp, Richard R

Mayo Clinic

Clinical and Translational Science | March 10, 2015 | Volume: 8 | Issue: 4 | Pages: 376-387

10.1111/cts.12268 | PMID 25758372 Get It

AbstractClinical research ethics consultation services have been established across academic health centers over the past decade. This paper presents the results of collaboration within the CTSA consortium to develop a standard approach to the collection of research ethics consultation information to serve as a foundation for quality improvement, education, and research efforts. This approach includes categorizing and documenting descriptive information about the requestor, research project, the ethical question, the consult process, and describing the basic structure for a consult note. This paper also explores challenges in determining how to share some of this information between collaborating institutions related to concerns about confidentially, data quality, and informatics. While there is much still to be learned to improve the process of clinical research ethics consultation, these tools can advance these efforts, which, in turn, can facilitate the ethical conduct of research.
Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve Replacement
Holmes, David R. , Brennan, James M. , Rumsfeld, John S., Dai, David , O’Brien, Sean M. , Vemulapalli, Sreekanth , Edwards, Fred H., Carroll, John D. , Shahian, David M. , Grover, Fred, Tuzcu, E. Murat , Brindis, Ralph G. , Mack, Michael J. , Peterson, Eric D.

Mayo Clinic

JAMA | March 10, 2015 | Volume: 313 | Issue: 10 | Pages: 1019

10.1001/jama.2015.1474 | PMID 25756438 Get It